Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Food and Metabolism Study (FAM)

Effects of Avocado on Triglyceride Metabolism in Individuals With Insulin Resistance

In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.

Panoramica dello studio

Descrizione dettagliata

The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. The research is designed as a randomized, 2-arm, parallel, diet-controlled, human clinical trial to investigate the effects of avocado consumption for 4 weeks on triglyceride metabolism in individuals with insulin resistance.

Participants will be asked to do the items described below. Visits will be held at the Clinical Nutrition Research Center (CNRC) on the Illinois Tech Campus, 10 W. 35th St., Suite 3D6-1 Chicago, IL, 60616.

SCREENING VISIT

Eligibility for the study is based on the above list (inclusion and exclusion criteria). Investigators will determine if participants qualify for the study at the Screening Visit by the following measurements:

  • General measurements: height, weight, body composition, waist circumference, blood pressure, vitals and body temperature
  • Fasting blood glucose (sugar) from a finger prick
  • Venous blood collection to assess blood glucose, insulin, and triglycerides
  • Pregnancy test, for women under the age of 60

Demographic questionnaire, health and medication questionnaire: participants will be asked to provide personal information, such as their name, date of birth, race, etc. Investigators will also ask them to answer questions about their demographics, health, medical history, and the medications they are taking. Based on the results of the blood draw, questionnaires, measurements, and evaluation of their health, they may meet the criteria and be invited to participate in the study.

PRE-STUDY / PRE-INTERVENTION VISIT (which may be performed on the same or a different day as the screening visit) The Pre-Study visit lasts ~45 minutes to 1 hour and participants will meet with one of our investigators who will provide detailed instructions on procedures of the study and "how to prepare for each of participants study days." They will be trained in all study procedures, including, but not limited to, foods to avoid during the study, medications/supplements to avoid, food diary recording, gastrointestinal diary recording and fasting overnight. Their study dates will be scheduled, and they will be provided with a study booklet, including a study calendar and all instructions covered at the Pre-Study Visit.

Medications/Supplements: If they are taking any medications or supplements that do not interfere with the study or have been OK'd by study staff, they will take those as instructed by their doctor and will record them in their diary. Investigators will train the participants on what foods or supplements are OK and NOT OK during the study at the Pre-Study Visit.

Self-Characteristics and Dietary Surveys: Participants will be asked to complete online surveys that cover usual gastrointestinal symptoms and a 24-hour food recall (https://asa24.nih.gov/).

STUDY DAY VISITS Study Visit 1 / Day 0 and Visit 5 / Day 28 Procedures

Staff collects study materials from the participant

1. Diary and provide 24 h recall (https://asa24.nih.gov/) Confirmation participant is ready to go for their study day by interview/discussion with the study staff

  1. Fasted overnight for 10-12 hours, including finger prick to verify usual fasting glucose
  2. Had a usual night of sleep (5-6 hours minimum)
  3. Avoided alcohol and vigorous physical activity 24 hours before the study day

After confirming they are ready for their study day, Investigators will proceed to an exam room to measure:

Anthropometrics: Investigators will measure weight, waist circumference and body composition.

Vital signs: Investigators will check their blood pressure, heart rate, and body temperature using standard clinic devices.

Once Investigators have collected measurements, they will proceed with an IV catheter to collect blood over multiple timepoints.

Blood collection: Participants will see the Licensed Health Care Provider (LHCP) for blood sample collection. Investigators will use an indwelling catheter (IV). This means Investigators will use a needle to put a thin tube in their arm or hand, from which Investigators can get blood samples while keeping them as comfortable as possible. This tube will stay in their arm until all blood drawings are completed during their visit. If there is difficulty with blood flow Investigators will ask the participant if they're comfortable with single stick blood collection, performed by LHCP using a butterfly needle. There will be nine blood draws in total over 5 hours.

Once the fasting blood draw is collected, Investigators will provide the participant with a breakfast in the form of a nutritionally complete liquid meal test (LMT).

Standard Liquid Meal Test (LMT): For this test, they will drink about 2 cups of vanilla flavored Ensure®. Ensure® is a nutritional supplement containing a mixture of sugars, fats, and protein and a variety of vitamins and minerals. The drink contains milk protein (suitable for lactose intolerance) and soy products. Investigators will ask if they are unwilling to consume any ingredients in the Ensure® drink. It may be unsafe for them to complete this test if they have an allergy to any of the components. The total amount participant will drink will be approximately 440 calories, 64g of Carbs, 12g of Fat, and 18g of Protein.

After all blood samples have been collected they will be provided with meals to last until V2 (~ 1 week) and instructed how to fill out the dietary adherence log.

MEAL PICKUP VISITS Study Visit 2 / Day 7, Study Visit 3 / Day 14, Study Visit 4 / Day 21

Participants will not need to come fasted for meal pickup visits. Investigators will collect materials and ensure they are complying with the study protocols, and assess if there are any difficulties Investigators can help with. The following will be done at pickup visits:

Staff collects study materials from the participant 1. Diary and provide 24 h recall (https://asa24.nih.gov/) Staff collects weight and LDN does counseling as needed

1. Licensed Dietitian Nutritionist (LDN) will review compliance diary and weight changes and provide nutrition counseling as needed

Tipo di studio

Interventistico

Iscrizione (Stimato)

82

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Illinois
      • Chicago, Illinois, Stati Uniti, 60616
        • Reclutamento
        • Clinical Nutrition Research Center at IIT

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Men or women, 40-70 years of age.
  • Fasting triglycerides (TG) >115 mg/dL.
  • Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) >2.5.
  • Able to provide informed consent.
  • Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (~ 80% of calories per day).
  • Able to come to the clinic up to 6 times during the study.
  • Able to maintain usual physical activity pattern.
  • Able to avoid/abstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.

Exclusion Criteria:

  • Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions.
  • Fasting blood sugar ≥125 mg/dL. Men and women with blood pressure >160 mmHg (systolic) / 100 mmHg (diastolic) at the screening visit.
  • Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.
  • Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.
  • Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.
  • Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.
  • Men and women who are not weight stable (+/-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.
  • Men and women with documented physical or mental disease/condition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.
  • Women who are known to be pregnant or who are intending to become pregnant over the course of the study.
  • Women who are lactating.
  • Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.
  • History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
  • Excessive coffee and tea consumers (> 4 cups/d).
  • Donated blood within the last 3 months.
  • Women who are taking an unstable dose and brand of hormonal contraceptives and/or a stable dose and brand for less than 6 months.
  • Unusual working hours (working overnight).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Avocado meal plan
2 meals and snack per day including one avocado in the meal, covering 80% of daily calories need.
American Diet with avocado
Comparatore placebo: Control meal plan
2 meals and snacks per day without the inclusion of avocado, covering 80% of daily calories needs.
American diet

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in serum biomarker: triglycerides
Lasso di tempo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in serum biomarker: insulin
Lasso di tempo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in serum biomarker: glucose
Lasso di tempo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in Muscle Insulin Sensitivity Index (MISI)
Lasso di tempo: baseline and 4 weeks
calculated using postprandial glucose and insulin concentrations measured by Randox clinical analyzer
baseline and 4 weeks
Changes in total cholesterol
Lasso di tempo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in free fatty acids
Lasso di tempo: baseline and 4 weeks
analyzed by Quest Diagnostics Lab
baseline and 4 weeks
Fructosamine
Lasso di tempo: baseline and 4 weeks
analyzed by Randox clinical analyzer
baseline and 4 weeks
Changes in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Lasso di tempo: baseline and 4 weeks
Calculated from fasting glucose and insulin
baseline and 4 weeks
Changes in Low-Density Lipoprotein (LDL) cholesterol
Lasso di tempo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in High-Density Lipoprotein (HDL) cholesterol
Lasso di tempo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in non-High-Density Lipoprotein (HDL) cholesterol
Lasso di tempo: baseline and 4 weeks
fasting state, analyzed by Labcorp
baseline and 4 weeks
Changes in Connecting Peptide (C-peptide)
Lasso di tempo: baseline and 4 weeks
analyzed by McLendon labs
baseline and 4 weeks
Changes in Glucagon-Like Peptide-1(GLP-1)
Lasso di tempo: baseline and 4 weeks
analyzed by Luminex multi-target analyzer
baseline and 4 weeks
Inflammation markers-Interleukin (IL)-6
Lasso di tempo: Baseline
Analyzed by Luminex method
Baseline
Inflammation markers-Interleukin (IL)-10
Lasso di tempo: Baseline
Analyzed by Luminex method
Baseline
Inflammation markers-Tumor necrosis factor alpha (TNF-α)
Lasso di tempo: Baseline
Analyzed by Luminex method
Baseline
Nuclear Magnetic Resonance (NMR) Lipoprotein Subfraction
Lasso di tempo: Baseline
Analyzed by Labcorp
Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Britt Burton-Freeman, PhD, Food Sci and Nut Programs

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 giugno 2026

Completamento primario (Stimato)

28 giugno 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

28 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 maggio 2026

Primo Inserito (Effettivo)

3 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

We would make all de-identified IPD collected during the trial (i.e., the study outcomes) publicly available upon request.

Periodo di condivisione IPD

January 1, 2028-no end date

Criteri di accesso alla condivisione IPD

A steering committee composed of primary investigators from the study approves or denies research proposals.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi